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Summary 
Background: Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and 
stroke. There is indirect evidence that agonists of peroxisome proliferator-activated receptor 7 (PPAR 7) could 
reduce macrovascular complications. Our aim, therefore, was to ascertain whether pioglitazone reduces 
macrovascular morbidity and mortality in high-risk patients with type 2 diabetes. 
Methods: We did a prospective, randomised controlled trial in 5238 patients with type 2 diabetes who had 
evidence of macrovascular disease. We recruited patients from primary-care practices and hospitals. We 
assigned patients to oral pioglitazone titrated from 15 mg to 45 mg (n=2605) or matching placebo (n=2633), to 
be taken in addition to their glucose-lowering drugs and other medications. Our primary endpoint was the 
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composite of all-cause mortality, non-fatal myocardial infarction (including silent myocardial infarction), stroke, 
acute coronary syndrome, endovascular or surgical intervention in the coronary or leg arteries, and amputation 
above the ankle. Analysis was by intention to treat. This study is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN NCT00174993. 
Findings: Two patients were lost to follow-up, but were included in analyses. The average time of observation 
was 34.5 months. 514 of 2605 patients in the pioglitazone group and 572 of 2633 patients in the placebo group 
had at least one event in the primary composite endpoint (HR 0•90, 95% CI 0•80-1•02, p=0•095). The main 
secondary endpoint was the composite of all-cause mortality, non-fatal myocardial infarction, and stroke. 301 
patients in the pioglitazone group and 358 in the placebo group reached this endpoint (0-84, 0-72-0-98, p=0-
027). Overall safety and tolerability was good with no change in the safety profile of pioglitazone identified. 6% 
(149 of 2065) and 4% (108 of 2633) of those in the pioglitazone and placebo groups, respectively, were admitted 
to hospital with heart failure; mortality rates from heart failure did not differ between groups. 
Interpretation: Pioglitazone reduces the composite of all-cause mortality, non-fatal myocardial infarction, and 
stroke in patients with type 2 diabetes who have a high risk of macrovascular events. 
 
INTRODUCTION 
Patients with type 2 diabetes are at high risk of fatal and non-fatal macrovascular events. These events are the 
main reason for their decreased life expectancy, which is about 8 years shorter in a 40-year-old patient newly 
diagnosed with diabetes than in the general population.1 There is a two-fold to four-fold increased risk of a 
macrovascular event in patients with, compared with those without, diabetes.2,3 Haffner and colleagues4 noted 
that the risk of a cardiovascular complication in a patient with diabetes was similar to that of a patient without 
diabetes who had had a myocardial infarction. In the Heart Protection Study,5 patients with diabetes and a history 
of cardiovascular disease at entry had almost a three-fold higher risk of a new cardiovascular event than did 
those without such a history. 
Intensive control of glycaemia decreases microvascular complications, such as retinopathy and nephropathy, but 
has no great effect on macrovascular complications or all-cause mortality. However, in the UK prospective 
diabetes study (UKPDS),6 findings of a retrospective analysis in a subgroup of 342 overweight patients who 
received metformin showed a significant decrease in cardiovascular disease and total mortality. 
Pioglitazone is an agonist of peroxisome proliferator-activated receptor γ (PPAR γ) used to treat type 2 diabetes.7 
The overall pattern of changes induced by pioglitazone suggests a general improvement in various risk factors 
that might reduce cardiovascular morbidity and mortality. Additionally, pioglitazone reduces the levels of 
various inflammatory markers, such as highly sensitive C-reactive protein (hsCRP), independently of its effect 
on glycaemic control.8
Our aim was to ascertain whether pioglitazone reduces cardiovascular morbidity and mortality in patients with 
type 2 diabetes, and to assess the safety and tolerability of such treatment. 
METHODS 
Patients 
The PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) protocol has been described 
in detail previously.9 Between May, 2001, and April, 2002, we recruited patients from primary-care practices and 
diabetic or cardiovascular specialist departments in hospitals to a randomised controlled trial. We included 
patients with type 2 diabetes who were aged 35-75 years if they had an haemoglobin Alc (HBAlc) concentration 
greater than the local laboratory equivalent of 6•5% for a Diabetes Control and Complications Trial-traceable 
assay (DCCT), despite existing treatment with diet alone or with oral glucose-lowering agents with or without 
insulin. Patients also had to have evidence of extensive macrovascular disease before recruitment, defined by one 
or more of the following criteria: myocardial infarction or stroke at least 6 months before entry to the trial, 
percutaneous coronary intervention or coronary artery bypass surgery at least 6 months before recruitment, acute 
coronary syndrome at least 3 months before recruitment, or objective evidence of coronary artery disease or 
obstructive arterial disease in the leg. Objective evidence of coronary artery disease was defined as a positive 
exercise test, angiography showing at least one stenosis of more than 50%, or positive scintigraphy. Obstructive 
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arterial disease of the leg was defined as a previous major amputation or intermittent claudication with an ankle 
or toe brachial pressure index of less than 0•9. 
We excluded patients if they: had type 1 diabetes; were taking only insulin; had planned coronary or peripheral 
revascularisation; had New York Heart Association class II heart failure or above; had ischaemic ulcers, 
gangrene, or rest pain in the leg; had had haemodialysis; or had greater than 2•5 times the upper limit of normal 
concentrations of alanine aminotransferase. 
All patients provided written informed consent. The study protocol was approved by local and national ethics 
committees and regulatory agencies, and was done in accordance with the Declaration of Helsinki and Good 
Clinical Practice guidelines. 
Procedures 
We randomly assigned patients to oral pioglitazone or matching placebo in addition to their existing 
medication(s) for diabetes. Study medication was assigned via a central interactive voice response system. 
Allocation of patients to treatment groups was done by the method of randomised permuted blocks within centre. 
All investigators and study personnel were unaware of treatment assignment for the duration of the study. Only 
the data and safety monitoring committee saw unblinded data, none of whom had any contact with the study 
participants. The randomisation sequence was generated by a member of the Statistics Department of 
Nottingham Clinical Research Limited. Once these lists had been checked, all files were passed on to the 
interactive voice response system coordinator, who maintained these files securely for the duration of the trial. 
The original lists were deleted by the Department of Statistics, who had no access to the randomisation code 
until the study was unblinded. Masking of drugs was achieved by using matching placebo. 
If allocated, we gave patients oral pioglitazone 15 mg for the first month, 30 mg for the second month, and 45 
mg thereafter to achieve the maximum tolerated dose, according to the licensed dose range for pioglitazone. At 
any time during the study, the dose of study drug could be adjusted within the same dose range if clinically 
indicated. Throughout the study, investigators were required to increase all therapy to an optimum, according to 
the International Diabetes Federation European Region 1999 guidelines.10 We drew particular attention to the 
need to reach an HBAlc concentration below the recommended target (<6•5%) and to increase to an optimum 
lipid-altering, antiplatelet, and antihypertensive therapy. 
We saw patients monthly for the first 2 months, then every 2 months for the first year, and thereafter every 3 
months until the final visit. We followed-up all patients until the end of the study even if they permanently 
ceased study medication before the study end. We measured vital signs and bodyweight at every visit. We 
obtained standard 12-lead electrocardiograms at the beginning of the study, at yearly intervals thereafter, and at 
the final visit. Two independent reviewers assessed all electrocardiograms for evidence of silent myocardial 
infarction on behalf of the endpoint adjudication committee. We took blood samples at baseline for central 
laboratory assessment of concentrations of HBAlc, triglyceride, HDL cholesterol, LDL cholesterol, alanine 
aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase, and creatinine. Thereafter, we 
measured HBAlc, fasting lipid, and creatinine concentrations every 6 months, and liver function at every visit in 
the first year and every 6 months in subsequent years. Urinary albumin concentration was measured locally at the 
beginning and at the end of the study, using Micral Test strips (Roche Diagnostics, Mannheim, Germany). We 
identified the presence of retinopathy, nephropathy, and neuropathy from the patients' records. Blood pressure 
was measured with routine clinical methods. 
All samples were measured in a central laboratory that participated in the appropriate national quality-control 
schemes for all analyses. We measured HDL-cholesterol and LDL-cholesterol concentrations with direct 
quantitative enzymatic methods, and triglyceride levels with a glycerol-blanked, enzymatic assay. Methods used 
to measure concentrations of HDL-cholesterol and triglycerides were accredited by the Centres for Disease 
Control Lipid Standardisation Program. We undertook all central laboratory methods on automated Hitachi 
(Tokyo, Japan) P-Modular platforms, using Roche reagents (Roche Diagnostics, Mannheim, Germany), with 
standards and controls as recommended by the manufacturer. We measured HBAlc concentrations in whole blood 
with a BIO-RAD-Variant ion exchange high-pressure liquid chromatography analyser (Biorad, Hercules, CA, 
USA), with standards and controls supplied by the manufacturer. The upper limit of normal for the laboratory 
was 6•4%. 
Our primary endpoint was time from randomisation to: all-cause mortality, non-fatal myocardial infarction 
(including silent myocardial infarction), stroke, acute coronary syndrome, endovascular or surgical intervention 
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on the coronary or leg arteries, or amputation above the ankle. We diagnosed a non-fatal myocardial infarction if 
the patient survived more than 24 h from onset of symptoms and, in the absence of percutaneous coronary 
intervention or coronary artery bypass graft, had at least two of: symptoms suggestive of myocardial infarction 
(ischaemic chest pain or discomfort) lasting 30 min or longer, electrocardiographic evidence of myocardial 
infarction, or raised cardiac serum markers; or after percutaneous coronary intervention or coronary artery 
bypass graft the patient had electrocardiographic evidence of myocardial infarction. Silent myocardial infarction 
was defined as new Q waves on two contiguous leads or R-wave reduction in the precordial leads without a 
change in axis deviation. Acute coronary syndrome was noted if the patients received treatment in hospital for 
ischaemic discomfort at rest that lasted at least 5 min and had electrocardiographic changes or raised cardiac 
serum markers not sufficiently high to indicate myocardial infarction, or both. Coronary revascularisation was 
when a patient underwent percutaneous transluminal coronary intervention—eg, angioplasty, stenting, 
atherectomy, laser ablation—or coronary artery bypass graft. Stroke was defined as acute focal neurological 
deficit lasting for longer than 24 h or resulting in death within 24 h of the onset of symptoms, which was 
diagnosed as being due to cerebral lesion of vascular origin but excluding subarachnoid haemorrhage. Major leg 
amputation included all amputations of the leg above the ankle. Revascularisation in the leg was noted if a 
patient underwent any of surgical bypass, atherectomy, angioplasty, or thrombolysis. 
The prespecified secondary endpoints, in order of priority, were: time to the first event of death from any cause, 
myocardial infarction (excluding silent myocardial infarction), and stroke (main secondary endpoint in rest of 
this report); cardiovascular death; and time to individual components of the primary composite endpoint. We 
classified all fatal events as cardiovascular unless there was a clear non-cardiovascular cause. 
We reported all potential endpoints and other serious adverse events to the coordinating centre within 1 working 
day of becoming aware of the event. We defined serious adverse events as: resulting in death, life-threatening, 
needing or prolonging in-patient admission, resulting in persistent or significant disability, or needing 
intervention to prevent any of the above. We elicited non-serious adverse events at every visit. Investigators were 
required to report, in particular, occurrences of symptoms compatible with hypogly-caemia, heart failure (as 
judged by the investigator), and oedema in the absence of heart failure, plus any adverse event leading to 
discontinuation of the study drug. 
Monitors reviewed patients' records regularly to ensure that all potential endpoints and other serious adverse 
events were being reported. All reports of serious adverse event were checked against the patients' clinical notes. 
An independent panel, working with the endpoint adjudication committee, assessed all potential endpoints and 
classified them in accord with predefined criteria. The study data and safety monitoring committee    supervised    
the study and assessed unblinded data to ensure the continued safety of participants throughout. 
Nottingham Clinical Research Group acted as a coordinating centre, providing project management, data 
management, central randomisation services, and statistical analysis. ICON Clinical Research managed and 
monitored the sites, and did central laboratory measurements. 
Statistical analysis 
Our planned study sample size of 5000 patients was based on the assumptions of a 6% annual primary event rate 
in the placebo group, recruitment of patients over 18 months, and a total trial duration of 4 years. A time-to-
event analysis was planned, and thus the study had 91% power to detect a 20% reduction in the hazard with a 
type I error of 0•05. To maintain this power, all patients had to be followed-up until at least 760 patients had one 
endpoint event or more. 
Since the event rate was higher than expected and the enrolment rate was faster than planned, the mean duration 
of exposure would have been shorter than originally anticipated. Therefore, to ensure sufficient duration of 
exposure, the protocol was amended in May, 2003, to specify that the trial should continue until the last patient 
recruited had been followed-up for 30 months and at least 760 patients had had one or more endpoint events. 
Two pre-planned interim analyses were done by the data and safety monitoring committee when about half and 
three-quarters of the target number of endpoints had been reached. We controlled the type I error with the 
method of Lan and Demets with the O'Brien-Fleming alpha spending function.11 The final analysis of the 
primary endpoint thus needed the observed significance level (two-sided) to be less than 0•044 for the treatment 
difference to be declared significant at the 5% level. 
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All time-to-event analyses were done by fitting a proportional hazards survival model with treatment as the only 
covariate. The proportional hazards assumption was tested with the method described by Grambsch and 
Therneau.12 Homogeneity of response was examined by testing for interaction in each of 25 prespecified sets of 
subgroups. We used linear models or logistic regression models for other endpoints, as appropriate. All analyses 
were by intention to treat. 
This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN 
NCT00174993. 
figure 1: Trial profile 
 
 
Role of the funding source 
The study was designed by the international steering committee, who also approved the protocol and 
amendments. The sponsors had two representatives on the international steering committee and the same two 
were also members of the executive committee. Data analysis, data interpretation, and writing of the report was 
done by the executive committee, with contributions from the international steering committee, the data and 
safety monitoring committee, and the endpoint adjudication committee. All the authors had full access to all the 
data in the study and had final responsibility for the decision to submit for publication. 
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Table 1: Baseline characteristics 
 Pioglitazone (n=2605) Placebo (n=2633) 
Patients' characteristics 
Male 1735(67%) 1728 (66%) 
White 2564(98%) 2600 (99%) 
Age (years) (mean, SD) 61•9 (7•6) 61•6(7•8) 
Time since diagnosis of diabetes (years) (median, IQR) 8 (4-13) 8(4-14) 
Body-mass index (kg/m²) (mean, SD) 307 (47) 31•0(4•8) 
Blood pressure: systolic/diastolic(mm Hg) (mean, SD) 144 (18)/83 (10) 143 (l8)/83 (9) 
History of hypertension 1947 (75%) 2005 (76%) 
Current smoker 340 (13%) 381 (14%) 
Past smoker 1199(46%) 1159(44%) 
Microvascular disease* 1113(43%) 1076 (41%) 
Blood glucose lowering treatment 
Metformin only 253 (10%) 261 (10%) 
Sulphonylureas only 508 (20%) 493 (19%) 
Metformin + sulphonylureas 654(25%) 660 (25%) 
Insulin only 5(<1%) 8(<1%) 
Insulin + metformin 456 (18%) 475 (18%) 
Insulin + sulphonylureas 209 (8%) 219 (8%) 
Insulin + metformin + sulphonylureas 105 (4%) 107 (4%) 
Other combination 306 (12%) 305 (12%) 
Diet only 109 (4%) 105 (4%) 
Laboratory data 
HBA1c(%) (median (IQR) 7•8 (7•0-8•9) 7•9(7•1-8•9) 
LDL cholesterol (mmol/L) (median, IQR) 2•9 (2•3-3•5) 2•9 (2•3-3•5) 
HDL cholesterol (mmol/L) (median, IQR) 1•1 (0•9-1•3) 1•1 (0•9-1•3) 
Triglycerides (mmol/L) (median, IQR) 1•8 (1•3-2•6) 1•8 (1•3-2•6) 
Creatinine (µmol/L) (median, IQR) 79 (68-92) 79 (68-92•5) 
Micral test result 
Negative 1407 (54%) 1428 (54%) 
About 20 mg/L 545 (21%) 551 (21%) 
About 50 mg/L 357(14%) 377 (14%) 
About 100 mg/L or more 232 (9%) 217 (8%) 
Data are number (%) unless otherwise stated, *Retinopathy, nephropathy, neuropathy. 
 
RESULTS 
Figure 1 shows the trial profile. 5238 patients from 321 centres in 19 European countries were randomly 
assigned to either pioglitazone (n=2605) or placebo (n=2633); 1681 patients were recruited from the community 
and 3557 from hospitals. All patients commenced study medication and all received their intended treatment. 
16% of patients assigned pioglitazone and 17% of those assigned placebo discontinued study medication before 
death or final visit (figure 1). We completed final visits between November, 2004, and January, 2005. The 
average time of observation was 34•5 months. Two patients were lost to follow-up. All other patients were 
followed-up to their final visit or death. The treatment code was broken for three patients (all placebo) during the 
study for medical or medicolegal reasons. 
The two groups were well matched with respect to baseline characteristics (table 1). Mean age overall was 61•8 
years, with the median time since diagnosis of diabetes being 8 years. At randomisation, 62% of patients were 
taking metformin and 62% were taking a sulphonylurea either as monotherapy or in combination for diabetes 
control. More than 30% of patients were on insulin. Contrary to the study entry criteria, 13 patients (0•2%) had 
insulin as their only glucose-lowering medication. 
Table 2 shows details of macrovascular disease and related concomitant medications taken. Patients had a high 
level of previous morbidity. We randomised 82 patients (2%) who we subsequently noted did not meet any of 
the strictly defined criteria for entry based on macrovascular history. Of these, 20 patients did not have any 
documented evidence of a previous macrovascular event. We included all 82 patients in all intention-to-treat 
analyses, but assigned them to the so-called absent subgroup for each of the subgroup analyses that related to 
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macrovascular entry criteria. 
Throughout, pioglitazone was well tolerated, with 89% (2235 of 2521) of patients reaching the 45 mg dose at the 
2-month visit compared with 91% (2293 of 2517) of matching placebo. Thereafter, at least 93% of patients 
continuing on pioglitazone received the highest dose compared with at least 95% of those on placebo. 
Compliance in both treatment groups, as defined by more than 75% of tablets used, was greater than 95%. 
Figure 2 shows Kaplan-Meier estimates of the proportion of patients reaching an event within the primary 
composite endpoint by treatment. Fewer patients in the pioglitazone group had at least one event than in the 
placebo group, though this finding was not significant. Figure 3 shows the Kaplan-Meier estimate of the 
proportion of patients reaching the main secondary endpoint of all-cause mortality, non-fatal myocardial 
infarction (excluding silent myocardial infarction), or stroke. Fewer patients in the pioglitazone than in the 
placebo group had at least one event. The difference was significant. There was no significant violation of the 
proportional hazards assumption (p=0•085 for the primary endpoint and p=0•616 for the main secondary 
endpoint). Table 3 shows the breakdown of event types within the primary and the main secondary endpoints. 
The four most frequent component endpoints were death, myocardial infarction, stroke, and coronary 
revascularisation. All are well represented in the primary composite endpoint, and the first three constitute the 
main secondary endpoint. There were 127 cardiovascular deaths in the group treated with pioglitazone compared 
with 136 in the placebo group. There were 50 non-cardiovascular deaths in each group. 
Table 4 shows the effect of pioglitazone on the first occurrence of each of the individual components of the 
primary composite endpoint and the total number of events reported. There is consistency of benefit across the 
endpoints of myocardial infarction, stroke, acute coronary syndrome, and cardiac intervention. The pioglitazone 
treated patients had 803 events, of which 514 were first events, whereas those on placebo had 900 events, of 
which 572 were first events. 
The statistical analysis plan identified 25 baseline variables for subgroup analysis. Interaction tests within these 
subgroups did not reveal evidence of heterogeneity. Table 5 shows the results of a multivariate analysis of the 
association of entry characteristics to the main secondary endpoint. Pioglitazone is associated with an HR of 
0•84 even after adjustment for the other factors in this table. An additional 14 factors at baseline—including, 
blood pressure, duration of diabetes, concentration of triglycerides and HDL cholesterol, and use of metformin 
and sulphonylurea— were considered but did not contribute significantly to the overall results. 
 
Table 2: Macrovascular morbidity at study entry and associated medications 
 Pioglitazone (n=2605) Placebo (n=2633) 
Entry criteria 
Previous myocardial infarction 1230 (47%) 1215 (46%) 
  Previous stroke 486 (19%) 498 (19%) 
Previous percutaneous intervention or coronary 804 (31%) 807(31%) 
artery bypass graft   
Previous acute coronary syndrome 355 (14%) 360 (14%) 
Objective evidence of coronary artery disease 1246 (48%) 1274(48%) 
Symptomatic peripheral arterial obstructive disease 504(19%) 539 (20%) 
Two or more macrovascular disease criteria 1223 (47%) 1278 (49%) 
Baseline cardiovascular medications 
β blockers 1423 (55%) 1434 (54%) 
Angiotensin-converting enzyme inhibitors 1630 (63%) 1658 (63%) 
Angiotensin II antagonists 170 (7%) 184 (7%) 
Calcium-channel blockers 892 (34%) 964 (37%) 
Nitrates 1018 (39%) 1045 (40%) 
Thiazide diuretics 401 (15%) 430 (16%) 
Loop diuretics 372 (14%) 378 (14%) 
Antiplatelet medications 2221(85%) 2175(83%) 
Aspirin 1942 (75%) 1888(72%) 
Statins 1108(43%) 1137 (43%) 
Fibrates 264(10%) 294(11%) 
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figure 2: Kaplan-Meier curve of time to primary endpoint* 
 
*Death from any cause, non-fatal myocardial infarction (including silent myocardial infarction), stroke, acute coronary syndrome, leg 
amputation, coronary revascularisation, or revascularisation of the leg. 
 
figure 3: Kaplan-Meier curve of time to main secondary endpoint* 
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Table 3: Numbers of first events contributing to the primary composite and main secondary endpoints 









Any endpoint 514 572 301 358 
Death 110 122 129 142 
Non-fatal Ml (excluding silent Ml) 85 95 90 116 
Silent Ml 20 23 NA NA 
Stroke 76 96 82 100 
Major leg amputation 9 15 NA NA 
Acute coronary syndrome 42 63 NA NA 
Coronary revascularisation 101 101 NA NA 
Leg revascularisation 71 57 NA NA 
MI=myocardial infarction. NA=not applicable. This table describes the events that make up the primary composite endpoint, so if death is 
not the first event, it does not appear. 
 
Table 4: Effect of pioglitazone and placebo on each component of the primary endpoint 





HR (95%Cl) Pioglitazone Placebo 
Death 177 186 0•96 (0•78-1•18) 177 186 
Non-fatal Ml (including silent Ml) 119 144 0•83 (0•65-1•06) 131 157 
Stroke 86 107 0•81 (0•61-1•07) 92 119 
Major leg amputation 26 26 1•01 (0•58-1•73) 28 28 
Acute coronary syndrome 56 72 0•78 (0•55-1•11) 65 78 
Coronary revascularisation 169 193 0•88 (0•72-1•08) 195 240 
Leg revascularisation 80 65 1•25 (0•90-1•73) 115 92 
Total    803 900 
Data refer to first event of that particular type. MI= myocardial infarction. 
 
Table 5: Hazard associated with relevant baseline characteristics* for the main secondary endpoint 
 HR (95%Cl) P 
Age (year) 1•05 (1•04-1•06) <0•0001 
Previous stroke 1•71(1•40-2•08) <0•0001 
Current smoker (vs never smoker) 1•70 (1•34-2•16) <0•0001 
Past smoker (vs never smoker) 1•19 (1•00-1•42) 0•0512 
Creatinine > 130 i-imol/L 1•67 (1•20-2•31) 0•0022 
Previous myocardial infarction 1•49 (1•25-1•78) <0•0001 
HBA„ >7-5% 1•48 (1•24-1•76) <0•0001 
Peripheral obstructive artery disease 1•35 (1•10-1•65) 0•0036 
Diuretic use 1•33 (1•13-1•57) 0•0007 
LDL cholesterol >4 mmol/L (vs <3 mmol/L) 1•33 (1•05-1•67) 0•0165 
LDL cholesterol 3-4 mmol/L (vs <3 mmol/L) 1•22 (1•01-1•46) 0•0357 
Insulin use 1•32 (1•12-1•55) 0•0008 
Percutaneous coronary intervention or coronary artery bypass graft 0•76 (0•63-0•93) 0•0083 
Statin use 0•83 (0•69-1•00) 0•0452 
Allocation to pioglitazone 0•84(0•72-0•98) 0•0309 
*Resulting from stepwise selection procedure (other variables considered: sex, body-mass index, duration of diabetes [<5 vs 5 to < 10 vs ≥ 
10 years], use of metformin versus sulphonylureas, combined blood pressure [low risk vs high risk], triglycerides [low risk vs at risk vs high 
risk], HDL cholesterol [low risk  vs at risk vs high risk], micral test results [positive vs negative], previous acute coronary syndrome, 
evidence of coronary artery disease, photocoagulation therapy, metabolic syndrome [present vs absent], use of β blockers, use of angiotensin-
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Table 6: Change in proportion of patients using concomitant medications 
Pioglitazone Placebo  
 Change from 
baseline 









Insulin 2•7% 866 (35•9%) 12-4% 1124 (46•4%) <0•0001 
Metformin -3•1% 1404 (58•1%) 1-8% 1543 (63•6%) 0•0001 
Sulphonylureas -9•0% 1286 (53•3%) -9-6% 1265 (52•2%) 0•449 
Thiazide diuretics 3•1% 447 (18•5%) 3-9% 490 (20•2%) 0•135 
Loop diuretics 7•7% 531 (22•0%) 5-4% 479 (19•8%) 0•056 
Antiplatelet medications 2•9% 2129 (88•2%) 5-1% 2126 (87•7%) 0•603 
Aspirin 1•7% 1841 (76•2%) 2-2% 1793 (73•9%) 0•065 
Statins 12•5% 1329 (55•0%) 12-3% 1346 (55•5%) 0•740 
Fibrates -1•5% 207 (8•6%) -1-1% 245 (10•1%) 0•067 
 
Table 6 shows how the use of concomitant medication changed during the course of the study. With the 
exception of insulin and metformin use—both of which rose more in the placebo group—use of particular 
medications rose or fell to a similar extent in patients treated with placebo and pioglitazone. 
At entry into the study, two thirds of patients were not receiving insulin (n=3478). Of these patients, 183 of 1741 
(11%) in the pioglitazone group and 362 of 1737 (21%) in the placebo group began to use insulin permanently 
(defined as insulin use for 90 days or more, or insulin use at death or end of study) during the course of the study 
(figure 4). 
As shown in table 7, concentrations of HBAlc and triglycerides decreased, and levels of HDL cholesterol 
increased, on pioglitazone relative to placebo. Although LDL-cholesterol concentrations increased marginally 
more on pioglitazone than on placebo, there was a greater decrease in the LDL cholesterol to HDL cholesterol 
ratio. Changes in microalbuminuria were similar in the two groups. Blood pressure was reduced slightly, but 
significantly (p=0•03), more in the pioglitazone treated group than in the placebo treated group (median change 
in systolic blood pressure 3 mm Hg vs 0 mm Hg). 
Table 8 summarises the incidence of serious adverse events that arose in more than 1% of patients. There were 
fewer serious adverse events in the pioglitazone group than in the placebo group, this difference indicating both 
the lower incidence of endpoint events and fewer other serious events. Table 9 shows the reporting rates of heart 
failure in the study. Despite the increase in reported heart failure in the pioglitazone group, the number of deaths 
from heart failure was similar in each group. Furthermore, 903 patients reported oedema without heart failure 
(562 pioglitazone, 341 placebo). Symptoms compatible with hypoglycaemia arose in 726 (28%) patients on 
pioglitazone and 528 (20%) on placebo, (p<0•0001) whereas hypoglycaemia that resulted in admission to 
hospital arose in 19 and 11 patients, respectively (p=0•14). Slightly more patients in the placebo group needed to 
be admitted for management of their diabetes. Overall, fewer patients who received pioglitazone were admitted 
to hospital than those on placebo (1145 [44%] vs 1217 [46%]). There was no difference in the overall incidence 
of malignant neoplasms. There were some imbalances in the incidence of individual tumours. There were more 
bladder tumours (14 vs six) and fewer cases of breast cancer (three vs 11) reported in the pioglitazone group 
compared with placebo. We noted no cases of acute liver toxicity, although there was a small reduction (median 
5%, IQR -27 to 20) in the alanine aminotransferase levels in the pioglitazone group compared with a small 
increase (8%, -17 to 38) in the placebo group. Increases of alanine aminotransferase to more than three times the 
upper limit of normal at any time during the study arose in 20 pioglitazone-treated and 33 placebo-treated 
patients. Creatinine values remained constant in both groups throughout the study. There was a 3•6 kg increase 
in mean bodyweight (range -30 to 29) in the pioglitazone group and a 0•4 kg decrease (-36 to 33) in the placebo 
group (p<0•0001). 
DISCUSSION 
Our findings show that pioglitazone non-significantly reduces the risk of the composite primary endpoint— 
death from any cause, non-fatal myocardial infarction (including silent myocardial infarction), stroke, acute 
coronary syndrome, leg amputation, coronary revascularisation, or revascularisation of the leg. The pre-defined 
main secondary endpoint—all-cause mortality, myocardial infarction, or stroke—was also reduced, significantly, 
in the pioglitazone group. Kaplan-Meier estimates indicate that allocation of 1000 patients to pioglitazone would 
avoid 21 first myocardial infarctions, strokes, or deaths over 3 years. In other words, 48 patients would need to 
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be treated for 3 years to avoid one first major cardiovascular event. This finding, however, might be an 
underestimate of the benefit of pioglitazone, since events subsequent to the initial one are also reduced. It is 
noteworthy that this improvement in outcome arose on top of normal medical care, which included glucose-
lowering, antiplatelet, antihypertensive, and lipid-altering therapies. Furthermore, the improvement was seen in a 
group of particularly ill patients who we selected on the basis of a macrovascular history. 
When the protocol was devised, we thought that the need for amputation, or cardiac or leg revascularisation, was 
likely to indicate macrovascular deterioration and would respond to therapy in a similar way to stroke and 
myocardial infarction. This hypothesis did not prove correct in the case of cardiac and leg revascularisation, 
perhaps because these endpoints are in part determined by the decision to intervene being based on local surgical 
or medical practice. All three outcomes of the main secondary endpoint were improved. The number of patients 
reporting an event that are discounted by moving from the primary to the principal secondary endpoint is the 
same (213, 214) in each group. 
Glycaemic control was better in the pioglitazone group than in the placebo group, despite an increased use of 
metformin and insulin in the placebo group; dyslipidaemia improved without any difference in the use of lipid-
altering agents. There was a small increase in LDL-cholesterol concentrations in the pioglitazone group, but the 
ratio of LDL cholesterol to HDL cholesterol improved more than on placebo. The increase in LDL-cholesterol 
concentrations could be related to a change in the distribution of LDL particles. Total LDL particles are reduced 
with pioglitazone.13 Therefore, the increase in concentrations of LDL cholesterol might not be considered 
adverse. 
Table7: Change in laboratory data from baseline to final visit 
 Pioglitazone Placebo P 
HBA1c (% absolute change) -0•8 (-1•6 to-0•1) -0•3 (-1•1 to 0•4) <0•0001 
Triglycerides (% change) -11•4(-34•4 to 18•3) 1•8 (-23•7 to 33•9) <0•0001 
LDL cholesterol (% change) 7•2 (-11•2 to 27•6) 4•9 (-13•9 to 23•8) 0•003 
H DL cholesterol (% change) 19•0 (6•6 to 33•3) 10•1 (-1•7 to 21•4) <0•0001 
LDL/HDL (% change) -9•5 (-27•3 to 10•1) -4•2 (-21•7 to 15•8) <0•0001 
Micral test results (baseline to final visit) 
   Improved (number, %) 492 of 2218 (22%) 451 of 2225 (20%) 0286 
   Worsened (number, %) 555 of 2218 (25%) 563 of 2225 (25%)  
Data are median (IQR) unless otherwise stated. 
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Table 8: Serious adverse event summary 
Pioglitazone (n=2605) Placebo (n=2633)  











Any serious adverse event 2720 1204(46%) 2978 1275 (48%) 0•110 
Endpoint events* 602 389 (15%) 686 434(16%) 0•123 
Non-endpoint events 2118 1079 (41%) 2292 1150 (44%) 0•099 
Most common events (excluding endpoints)  † 
Angina pectoris 107 89 (3%) 145 122 (5%) 0•025 
Hospital admission for diabetes 
control 
57 55(2%) 99 91 (3%) 0•003 
Accident 53 51(2%) 50 49 (2%) 0•798 
Atrial fibrillation 47 42 (2%) 60 51 (2%) 0•374 
Pneumonia 57 53 (2%) 37 35 (1%) 0•047 
Transient ischaemic attack 39 34(1%) 42 39 (2%) 0•587 
Neoplasms 118 112 (4%) 117 113 (4%)  
   Malignant ‡ 103 97 (4%) 103 99 (4%)  
     Colon/rectal  16 (1%)  15 (1%) 0•834 
     Lung  15 (1%)  12 (1%) 0•544 
     Bladder  14 (1%)  6 (<1%) 0•069 
     Bladder (after exclusion) §  6 (<1%)  3 (<1%) 0•309 
     Haematological  6 (<1%)  10 (<1%) 0•327 
     Breast  3 (<1%)  11 (<1%) 0•034 
     Other  47 (2%)  46 (2%) 0•876 
*Does not include silent myocardial infarctions or events resulting in death, † Events reported by more than 1% of patients, excluding heart 
failure (see table 9), ‡ Some patients had more than one tumour type, § Cases remaining after blinded review, see main text for details. 
 
Table 9: Reports of heart failure 












Any report of heart failure* 417 281 (11%) 302 198 (8%) <0•0001 
Heart failure not needing 160 132 (5%) 117 90 (3%) 0•003 
hospital admission*      
Heart failure needing 209 149 (6%) 153 108 (4%) 0•007 
hospital admission*      
Fatal heart failure  † 25 25 (1%) 22 22 (1%) 0•634 
*Not adjudicated.  † Adjudicated cause of death. 
 
How pioglitazone improved cardiovascular outcome in our patients is unclear. The pioglitazone-treated group 
had a better metabolic profile in terms of glucose, HDL cholesterol, and triglyceride concentrations, and a better 
blood-pressure profile at the end of the study than at the beginning. The improvement in glycaemic control arose 
despite the fact that investigators were urged to adhere to the 1999 International Diabetes Federation guidelines 
and targets for the management of their patients and could alter background medication. Indeed, this requirement 
explains in part the increased use of insulin and metformin in the placebo group. The improvement in 
concentrations of triglycerides and HDL cholesterol are also of significant magnitude, and might have 
contributed to the outcome. The difference in LDL-cholesterol concentrations between the groups is unlikely to 
be of clinical significance. Although small, the difference in blood pressure between the groups might, however, 
have contributed to the outcome. Reaven14 has proposed that insulin resistance is the link between 
hyperglycaemia, dyslipidaemia, hypertension, and macrovascular disease. Thiazolidinediones, such as 
pioglitazone, improve insulin sensitivity through their effect on the PPAR γ receptor. This mechanism could be 
the link between treatment and reduced risk of macrovascular disease in patients with diabetes, but further work 
is needed to confirm this notion. 
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We also noted a reduced need to start taking insulin while on pioglitazone compared with placebo. The hazard 
reduction of 50% could indicate that doctors treating patients in the control group, who were unable to prescribe 
pioglitazone, used insulin instead to try to improve glycaemic control. Alternatively, pioglitazone might reduce 
the concentration of glucose in the blood to below a threshold at which insulin would be used. Finally, as 
previously suggested, pioglitazone could have a specific (β-cell sparing effect, manifest in other clinical studies 
by a reduction of circulating insulin,15 and in animal studies by regranulation of the β cell.16
We believe our results are generalisable to all patients with type 2 diabetes. We recruited patients from 19 
countries in Europe; both from primary-care and secondary-care settings. Individuals were at high risk of 
macrovascular events by virtue of the entry criteria, which required evidence of macrovascular disease. 
Furthermore, patients were on a wide range of glucose-lowering medications, including insulin. The beneficial 
effects of pioglitazone are apparent in patients who take insulin as well as in those who do not, and are 
independent of the use of other oral glucose-lowering treatments. Our results should also be applicable to 
patients who have not had a macrovascular event, since virtually all patients with type 2 diabetes develop 
atherosclerotic disease and there is a two-fold to fourfold increased risk in those with, compared to those 
without, diabetes. Since our subgroup analyses did not reveal any great heterogeneity across the 25 variable 
categories (a total of 56 subgroups), the overall estimate of efficacy provides the best estimate of effect for all 
subgroups. 
The results of the Universities Group Diabetes Programme17 and UKPDS18 indicated no clear improvements in 
cardiovascular outcomes after an intensive blood glucose-lowering regimen in patients newly diagnosed with 
type 2 diabetes. Findings of a subsequent analysis6 of patients in UKPDS who were obese and who took 
metformin as the main treatment for their diabetes rather than conventional, non-intensive therapy, showed a 
significant improvement in macrovascular outcomes. However, in obese patients given metformin as an adjunct 
to sulphonylurea there was a non-significant, increase in cardiovascular events. 
Compared with placebo, we noted no excess deaths in the pioglitazone group, and identified no liver toxicity. 
Slightly fewer patients in the pioglitazone group reported non-endpoint serious adverse events than in the 
placebo group. Consistent with the reported side-effect profile for pioglitazone, there was an increased rate of 
oedema and heart failure, though mortality due to heart failure did not differ between groups. The increased 
reporting of heart failure in the pioglitazone group might, at least in part, indicate a diagnostic bias because of 
the increased oedema in the pioglitazone group. It is noteworthy that heart failure was not a centrally adjudicated 
event. The adverse-event profile was otherwise unremarkable. 
The data and safety monitoring committee reviewed the 20 bladder cases with external experts (S Cohen, 
University of Nebraska Medical Center, and D Phillips, UK Institute of Cancer Research) before the study was 
unblinded. The experts considered that the 11 tumours that occurred within 1 year of randomisation (eight 
pioglitazone, three placebo) could not plausibly be related to treatment. After unblinding, there remained nine 
cases: six and three cases in the pioglitazone and placebo groups, respectively. Of these, four and two cases had 
known risk factors in their history (smoking, exposure to potential carcinogens, family history, previous tumour, 
urinary tract infection). Taking into account the timeframe of these cases and the potential confounding factors, it 
is improbable that the imbalance is related to pioglitazone treatment. 
In summary, in patients with type 2 diabetes who are at high cardiovascular risk, pioglitazone improves 
cardiovascular outcome, and reduces the need to add insulin to glucose-lowering regimens compared with 
placebo. 
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